#### Edgar Filing: ENDO HEALTH SOLUTIONS INC. - Form 4

ENDO HEALTH SOLUTIONS INC. Form 4 March 03, 2014 OMB APPROVAL FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... 0.5 Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person \* 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading DeGolyer Donald W Issuer Symbol ENDO HEALTH SOLUTIONS INC. (Check all applicable) [ENDP] (Last) (First) (Middle) 3. Date of Earliest Transaction Director 10% Owner X\_Officer (give title Other (specify (Month/Day/Year) below) below) C/O ENDO HEALTH SOLUTIONS 02/28/2014 Chief Operating Officer, Pharma INC., 1400 ATWATER DRIVE (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) \_X\_ Form filed by One Reporting Person \_ Form filed by More than One Reporting MALVERN, PA 19355 Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities Acquired 5. Amount of 6. 7. Nature of Security (Month/Day/Year) Execution Date, if Transaction(A) or Disposed of Securities Ownership Indirect (Instr. 3) any Code (D) Beneficially Form: Beneficial (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) Owned Direct (D) Ownership or Indirect Following (Instr. 4) Reported (I)(A) Transaction(s) (Instr. 4) or (Instr. 3 and 4) (D) Price Code V Amount 2010 Stock Incentive Plan Restricted 02/28/2014 D 30,604 D (2)0 D Stock Units (RSU) (1) (2)2010 Stock Incentive Plan Restricted 02/28/2014 D 5.121 D <u>(3)</u> 0 D Stock Units (RSU) (3)<u>(4)</u> 02/28/2014 D 30,604 D 0 D

### Edgar Filing: ENDO HEALTH SOLUTIONS INC. - Form 4

|  |   | 5 (                                     |   |        |   |        |                     |   |                 |                                     |  |  |  |
|--|---|---|---|--------|---|--------|---------------------|---|-----------------|-------------------------------------|--|--|--|
| 2010 Stoc<br>Incentive<br>Performar<br>Shares (4)  | Plan  |   |   |        |   |        |                     |   |                 |                                     |  |  |  |
| 2010 Stock<br>Incentive Plan<br>Performance<br>Shares (5) D  |   |   | 10,24   | 2 D    | <u>(5)</u>  | 0      | D                   |   |                 |                                     |  |  |  |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number. |   |   |   |        |   |        |                     |   |                 |                                     |  |  |  |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned         (e.g., puts, calls, warrants, options, convertible securities)   |   |   |   |        |   |        |                     |   |                 |                                     |  |  |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)  | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | Code   | 5. Number of<br>nsactiorDerivative<br>e Securities<br>(Month/Day/Year)<br>rr. 8) Acquired (A)<br>or Disposed of<br>(D)<br>(Instr. 3, 4,<br>and 5) |        | Date                | 7. Title and Amount of<br>Underlying Securities<br>(Instr. 3 and 4) |                 |                                     |  |  |  |
|  |   |   |   | Code V | (A)   | (D)    | Date<br>Exercisable | Expiration<br>Date  | Title           | Amount<br>or<br>Number<br>of Shares |  |  |  |
| 2010<br>Stock<br>Incentive<br>Plan<br>Stock<br>Options<br>(NQ) (6)   | \$ 79.33  | 02/28/2014                              |   | D      |   | 19,081 | <u>(6)</u>          | 02/26/2024  | Common<br>Stock | 19,081                              |  |  |  |
| Reporting Owners   |   |   |   |        |   |        |                     |   |                 |                                     |  |  |  |

#### **Reporting Owners**

| <b>Reporting Owner Name / Address</b>  | Relationships |           |                                |       |  |  |  |
|--|---------------|-----------|--------------------------------|-------|--|--|--|
|  | Director      | 10% Owner | Officer                        | Other |  |  |  |
| DeGolyer Donald W<br>C/O ENDO HEALTH SOLUTIONS INC.<br>1400 ATWATER DRIVE<br>MALVERN, PA 19355 |               |           | Chief Operating Officer,Pharma |       |  |  |  |

## Signatures

/s/ Caroline B. Manogue, by power of attorney

03/03/2014 Date

# <u>\*\*Signature of Reporting Person</u> Explanation of Responses:

- If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On February 28, 2014, Endo Health Solutions, Inc. ("Endo") and Paladin Laboratories Inc. ("Paladin") consummated a transaction under an arrangement agreement pursuant to which each of Endo and Paladin was acquired by a new Irish holding company, Endo International plc ("New Endo"). Under the terms of the arrangement agreement (a) New Endo acquired Paladin pursuant to a plan of arrangement

(1) pic (New Endo ). Onder the terms of the arrangement agreement (a) New Endo acquired ratadin pursuant to a plan of arrangement agreement (a) New Endo acquired ratadin pursuant to a plan of arrangement under Canadian law and (b) a newly formed subsidiary of New Endo merged with and into Endo, with Endo as the surviving corporation in the merger (the "Merger") and an indirect wholly owned subsidiary of New Endo. At the effective time of the Merger, each Endo equity security was cancelled and converted into the right to receive one equivalent New Endo equity security.

(2) These restricted stock units granted on August 2, 2013 under the 2010 Stock Incentive Plan, of which none are vested as of February 28, 2014 with the unvested portion generally vesting 33-1/3% annually at each future grant date anniversary through August 2, 2016, were assumed by New Endo in the Merger and converted into New Endo restricted stock units with the same terms and conditions as the original Endo restricted stock units.

(3) These restricted stock units granted on February 26, 2014 under the 2010 Stock Incentive Plan, of which none are vested as of February 28, 2014 with the unvested portion generally vesting 25% annually at each future grant date anniversary through February 26, 2018, were assumed by New Endo in the Merger and converted into New Endo restricted stock units with the same terms and conditions as the original Endo restricted stock units.

These performance share units granted on August 2, 2013 under the 2010 Stock Incentive Plan were assumed by New Endo in the Merger and converted into New Endo performance share units with the same terms and conditions as the original Endo performance share units. These performance shares vest on August 2, 2016 upon the Company achieving certain shareholder return targets over the period

(4) beginning on August 2, 2013 and ending on August 2, 2016. The amount of performance share units included in this line represents the target quantity of shares issuable. The exact number of shares issuable, between 0% and 300% of the target shares, will be based on achievement, as determined by the Compensation Committee of the Board of Directors of Endo, of the specified shareholder return targets over the cumulative 3-year period set forth above.

These performance share units granted on February 26, 2014 under the 2010 Stock Incentive Plan were assumed by New Endo in the Merger and converted into New Endo performance share units with the same terms and conditions as the original Endo performance share units. These performance shares vest on February 26, 2017 upon the Company achieving certain shareholder return targets over the period

(5) beginning on February 26, 2014 and ending on February 26, 2017. The amount of performance share units included in this line represents the target quantity of shares issuable. The exact number of shares issuable, between 0% and 300% of the target shares, will be based on achievement, as determined by the Compensation Committee of the Board of Directors of Endo, of the specified shareholder return targets over the cumulative 3-year period set forth above.

These non-qualified stock options granted on February 26, 2014 under the 2010 Stock Incentive Plan, of which none are vested as of February 28, 2014 with the unvested portion generally vesting 25% per year on each grant date anniversary through February 26, 2018,

(6) recruit y 20, 2014 with the universe portion generally vesting 20 // per year on each grant date anniversary through reordary 20, 2016, were assumed by New Endo in the Merger and converted into options to purchase ordinary shares of New Endo for the listed exercise price per share with the same terms and conditions as the original Endo stock options.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.